Your session is about to expire
← Back to Search
This trial tests a drug to see if it works to treat advanced solid tumors with HER2. It also looks at safety and side effects.
- Ovarian Tumors
- Endometrial Cancer
- Squamous Cell Carcinoma
- Non-Small Cell Lung Cancer
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Are there still spots available in this medical trial?
"Confirmation on clinicaltrials.gov reveals that participant recruitment for this trial is ongoing and the study was originally posted to the website on November 30th 2023, with its most recent update being made September 15th 2023."
Has the Disitamab vedotin single-drug approach gained regulatory approval?
"The safety profile of Disitamab vedotin monotherapy is assessed a 2 as there are some data points suggesting its relative security, but no evidence has been collected to verify its efficacy."
How many distinct sites are carrying out this research?
"At this moment, 4 trial sites are operational and actively taking on new participants. Norwich, Canton, El Paso will be the most accessible for many people; however other locations exist if that is more convenient."
How many individuals have thus far enrolled in this experiment?
"Affirmative, clinicaltrials.gov indicates that this research is actively engaging patients to take part in the experiment. It was initially posted on November 30th 2023 and has since been revised as of September 15th 2023. This trial needs 190 individuals across 4 sites for full enrollment completion."
Share this study with friends